LEI:
549300Q7EXQQH6KF7Z84
05 April
2024
RTW Biotech Opportunities
Ltd
New Investment in Obsidian
Therapeutics, Inc.
•
|
RTW Bio participated in oversubscribed $160.5 million Series C
Financing
|
•
|
Obsidian is a clinical-stage biotech company pioneering
engineered cell and gene therapies
|
•
|
Proceeds to support the development of OBX-115 for metastatic
melanoma and non-small cell lung cancer
|
RTW Biotech Opportunities Ltd (the
"Company"), a London Stock Exchange-listed investment company
focused on identifying transformative assets with high growth
potential across the life sciences sector, is pleased to note the
announcement by new private portfolio company, Obsidian
Therapeutics, Inc. ("Obsidian") of its completion of a
$160.5 million Series C financing round.
The Company, alongside other
investment vehicles managed by RTW Investments, LP (the
"Investment Manager"),
participated in the financing round with other life science
investment firms. Obsidian intends to use
the net proceeds to support clinical
development of OBX-115 in ongoing clinical trials for patients with
metastatic melanoma and non-small cell lung cancer.
Obsidian Therapeutics is a
clinical-stage biotechnology company pioneering engineered cell and
gene therapies to deliver transformative outcomes for patients with
intractable diseases. Obsidian's proprietary technology is designed
to precisely regulate the timing and level of protein function by
using FDA-approved small-molecule drugs. The Company has
collaborations with Bristol Myers Squibb and Vertex
Pharmaceuticals.
Lauren Lee, PhD, Research Analyst at
the Investment Manager, said, "We are
pleased to support Obsidian in this Series C financing to progress
the development of OBX-115, a next-generation tumour-infiltrating
lymphocyte (TIL) therapy in ongoing clinical studies that could
transform outcomes for melanoma and non-small cell
lung cancer patients."
The full text of these announcements
can be accessed on Obsidian's website:
https://obsidiantx.com/.
For
Further Information
RTW
Investments, LP
|
+44
20 7959 6361
|
Woody Stileman, Managing Director,
Business Development
Krisha McCune, Director, Investor
Relations
|
biotechopportunities@rtwfunds.com
|
|
|
Buchanan (PR & Communications Adviser)
|
+44
20 7466 5107
|
Charles Ryland
|
|
Henry Wilson
|
|
George Beale
|
|
|
|
Deutsche Numis (Joint Corporate Broker)
|
+44
20 7260 1000
|
Freddie Barnfield
|
|
Nathan Brown
|
|
Euan Brown
|
|
|
|
BofA Securities (Joint Corporate Broker)
|
+44
20 7628 1000
|
Edward Peel
|
|
Alex Penney
|
|
Cadarn Capital (Distribution & IR
Partner)
|
+44
73 6888 3211
|
David Harris
|
|
Elysium Fund Management Limited
Joanna Duquemin Nicolle, Chief
Executive Officer
Sadie Morrison, Managing
Director
|
+44
14 8181 0100
|
Morgan Stanley Fund Services USA LLC
|
+1
914 225 8885
|
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW & RTWG) is an investment fund focused on identifying
transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a
long-term approach to support innovative businesses, RTW Biotech
Opportunities Ltd invests in companies developing next-generation
therapies and technologies that can significantly improve patients'
lives. RTW Biotech Opportunities Ltd is managed by RTW Investments,
LP, a leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.
***********
The information in this announcement
may include forward-looking statements, which are based on the
current expectations and projections about future events, and in
certain cases can be identified by the use of terms such as "may",
"will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives
thereon) or other variations thereon or comparable terminology.
These forward-looking statements, as well as those included in any
related materials, are subject to risks, uncertainties and
assumptions about the Company and/or its underlying investments,
including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use
of financing proceeds and future capital expenditures and
acquisitions. In light of these risks, uncertainties and
assumptions, the events in the forward-looking statements may not
occur.
The information contained in this
announcement is given at the date of its publication (unless
otherwise marked). No reliance may be placed for any purpose
whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or
fairness.
***********